These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37236818)

  • 21. Liposome-based dry powder vaccine immunization targeting the lungs induces broad protection against pneumococcus.
    Rodrigues TC; Figueiredo DB; Gonçalves VM; Kaneko K; Saleem IY; Miyaji EN
    J Control Release; 2024 Apr; 368():184-198. PubMed ID: 38395155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new candidate epitope-based vaccine against PspA PhtD of
    Shafaghi M; Bahadori Z; Barzi SM; Afshari E; Madanchi H; Mousavi SF; Shabani AA
    Front Cell Infect Microbiol; 2023; 13():1271143. PubMed ID: 38035337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines.
    Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LCC
    Microb Pathog; 2017 Aug; 109():233-238. PubMed ID: 28602840
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
    Genschmer KR; Accavitti-Loper MA; Briles DE
    Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Combination of Recombinant Mycobacterium bovis BCG Strains Expressing Pneumococcal Proteins Induces Cellular and Humoral Immune Responses and Protects against Pneumococcal Colonization and Sepsis.
    Goulart C; Rodriguez D; Kanno AI; Converso TR; Lu YJ; Malley R; Leite LCC
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28768668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.
    Chen A; Mann B; Gao G; Heath R; King J; Maissoneuve J; Alderson M; Tate A; Hollingshead SK; Tweten RK; Briles DE; Tuomanen EI; Paton JC
    Clin Vaccine Immunol; 2015 Oct; 22(10):1079-89. PubMed ID: 26245351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge.
    Campos IB; Darrieux M; Ferreira DM; Miyaji EN; Silva DA; Arêas AP; Aires KA; Leite LC; Ho PL; Oliveira ML
    Microbes Infect; 2008 Apr; 10(5):481-8. PubMed ID: 18403234
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of four adjuvants revealed the strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant.
    Chen X; Li B; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Zhang Y; Wu Y
    Med Microbiol Immunol; 2019 Apr; 208(2):215-226. PubMed ID: 30707297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a vaccine formulation against Streptococcus pneumoniae based on choline-binding proteins.
    Miyaji EN; Vadesilho CF; Oliveira ML; Zelanis A; Briles DE; Ho PL
    Clin Vaccine Immunol; 2015 Feb; 22(2):213-20. PubMed ID: 25520146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
    Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
    Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.
    Langermann S; Palaszynski SR; Burlein JE; Koenig S; Hanson MS; Briles DE; Stover CK
    J Exp Med; 1994 Dec; 180(6):2277-86. PubMed ID: 7964500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
    Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
    Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bivalent conjugate vaccine containing PspA families 1 and 2 has the potential to protect against a wide range of Streptococcus pneumoniae strains and Salmonella Typhi.
    Kothari N; Kothari S; Choi YJ; Dey A; Briles DE; Rhee DK; Carbis R
    Vaccine; 2015 Feb; 33(6):783-8. PubMed ID: 25545593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant BCG expressing a PspA-PdT fusion protein protects mice against pneumococcal lethal challenge in a prime-boost strategy.
    Goulart C; Rodriguez D; Kanno AI; Lu YJ; Malley R; Leite LC
    Vaccine; 2017 Mar; 35(13):1683-1691. PubMed ID: 28242071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.